You’re Not ‘Hacking Your Gut’—You’re Getting 3 Different Diagnoses From the Same Poop Sample (and the Study That Finally Proved It)
A 2026 peer‑reviewed study sent three identical NIST stool samples to seven direct‑to‑consumer microbiome testing services—and got meaningfully different results. If the input is the same but the “truth” changes, the instability isn’t your gut—it’s the measurement.
By TheMurrow Editorial
March 28, 2026
Key Points
- 1A 2026 study sent three identical NIST stool samples to seven DTC services—and got meaningfully different microbial profiles back.
- 2Recognize that analytical pipelines (methods, databases, thresholds, scoring) can drive contradictions even when biology is held constant.
- 3Treat gut “health scores” and prescriptive supplement advice as company-specific interpretations—not stable diagnoses—until standards and reproducibility improve.
You mail off a vial of stool, wait a couple of weeks, and receive a glossy report that reads like a fortune cookie with footnotes: your gut is “imbalanced,” your “diversity” is “suboptimal,” and a handful of foods are suddenly villains. The advice feels intimate—microbial, personal, data-driven. It also feels, for many consumers, confusingly unstable.
Run the same test again. Or, more commonly, try a different company. Plenty of people report the same whiplash: three tests, three different stories. One service praises your microbiome’s “resilience.” Another flags a red-alert “dysbiosis.” A third swears you’re missing microbes you were apparently abundant in last month.
For years, scientists have explained some of this away as biology. The gut microbiome is dynamic, influenced by diet, sleep, stress, medication, illness, and ordinary randomness. That’s true. The more uncomfortable possibility is that the problem isn’t you at all.
The study that finally put the instability under a bright light
A peer-reviewed study published in Communications Biology in February 2026 put that possibility under a bright, standardized light. Researchers sent three identical fecal samples—not three similar samples, not three consecutive days, but the same standardized stool reference material developed at NIST—to seven direct-to-consumer microbiome testing services. The companies sent back meaningfully different results.
When identical samples produce different microbial “truths,” the problem stops looking like biology and starts looking like measurement.
— — TheMurrow
The promise of gut microbiome tests—and the moment they overreach
Direct-to-consumer (DTC) microbiome tests sell a compelling narrative: your gut is an ecosystem, and modern sequencing can map it. Most services offer some mix of three things: a taxonomy snapshot (which microbes are “present” and in what relative abundance), a composite score (often called a “gut health score” or “balance” metric), and personalized advice—typically diet changes, plus supplements or probiotics.
The appeal is obvious. Consumers want actionable health information without waiting for clinical appointments. Microbiome science is also genuinely fascinating, with credible links to digestion, immune function, and metabolism. The marketing bridge from “interesting correlations” to “personalized guidance” can feel short.
Independent investigations, however, have repeatedly warned that standardization is thin and interpretation often outpaces evidence. A 2024 review indexed on PubMed highlighted the central tension: the tests can produce detailed lists, but clinical meaning remains uncertain for many outputs, especially when companies wrap them in health scores and recommendations without a validated medical framework.
The appeal is obvious. Consumers want actionable health information without waiting for clinical appointments. Microbiome science is also genuinely fascinating, with credible links to digestion, immune function, and metabolism. The marketing bridge from “interesting correlations” to “personalized guidance” can feel short.
Independent investigations, however, have repeatedly warned that standardization is thin and interpretation often outpaces evidence. A 2024 review indexed on PubMed highlighted the central tension: the tests can produce detailed lists, but clinical meaning remains uncertain for many outputs, especially when companies wrap them in health scores and recommendations without a validated medical framework.
Why consumers keep getting “three different diagnoses”
Variability has two parents.
One is biology: your microbiome changes, and stool sampling itself can be finicky. The other is analytics: what happens after the sample leaves your hands. That second category includes laboratory methods, sequencing choices, reference databases, computational pipelines, thresholds for detection, and even how a company defines a category like “healthy.”
Researchers have been increasingly blunt about this. The alarming pattern isn’t simply that two people have different microbiomes. It’s that even when biology is held constant, company reports can diverge sharply—suggesting analytical variability is a major driver, not just natural fluctuation.
One is biology: your microbiome changes, and stool sampling itself can be finicky. The other is analytics: what happens after the sample leaves your hands. That second category includes laboratory methods, sequencing choices, reference databases, computational pipelines, thresholds for detection, and even how a company defines a category like “healthy.”
Researchers have been increasingly blunt about this. The alarming pattern isn’t simply that two people have different microbiomes. It’s that even when biology is held constant, company reports can diverge sharply—suggesting analytical variability is a major driver, not just natural fluctuation.
The industry’s quiet assumption has been: “Your microbiome varies.” The harder question is: “How much do the results vary because the test does?”
— — TheMurrow
The 2026 study: identical stool samples, seven services, seven stories
The February 2026 Communications Biology paper—titled “Evaluating the analytical performance of direct-to-consumer gut microbiome testing services”—did something consumer microbiome testing has needed for a long time: it reduced the role of “real biology” to near zero.
Researchers used a homogeneous stool reference material developed at the National Institute of Standards and Technology (NIST). Instead of sending companies samples from different people, they sent three identical fecal samples made from standardized material. Seven DTC services participated in the assessment.
The brilliance of this design is its simplicity. If every company receives the same material and still returns meaningfully different microbial profiles, the discrepancy can’t be pinned on what the person ate yesterday. The variability has to be located inside the testing services themselves—methods, databases, or interpretation.
Secondary coverage captured the starkness of the results. Science News reported that the companies returned different answers about which microbes were present and at what levels, even though the input was identical. The scale of disagreement wasn’t subtle: the variability between companies on the standardized sample was described as similar in magnitude to variability among samples from different people.
That is an extraordinary finding with immediate consumer relevance. It suggests that, for at least some outputs, “switching companies” can resemble “switching bodies.”
Researchers used a homogeneous stool reference material developed at the National Institute of Standards and Technology (NIST). Instead of sending companies samples from different people, they sent three identical fecal samples made from standardized material. Seven DTC services participated in the assessment.
The brilliance of this design is its simplicity. If every company receives the same material and still returns meaningfully different microbial profiles, the discrepancy can’t be pinned on what the person ate yesterday. The variability has to be located inside the testing services themselves—methods, databases, or interpretation.
Secondary coverage captured the starkness of the results. Science News reported that the companies returned different answers about which microbes were present and at what levels, even though the input was identical. The scale of disagreement wasn’t subtle: the variability between companies on the standardized sample was described as similar in magnitude to variability among samples from different people.
That is an extraordinary finding with immediate consumer relevance. It suggests that, for at least some outputs, “switching companies” can resemble “switching bodies.”
3 identical samples
Researchers sent three identical fecal samples made from standardized NIST stool reference material—reducing “real biology” variability to near zero.
7 services
Seven direct-to-consumer microbiome testing services participated—and returned meaningfully different microbial profiles from the same input.
Between-company variability ≈ between-person variability
Science News reported the disagreement across companies was similar in magnitude to differences seen among samples from different people.
A caution about “ground truth”—and what the study actually proves
A valuable nuance came through in an ACS/C&EN briefing: a NIST author emphasized that pinning down the “true” composition of even a standard stool sample with enough certainty to serve as an absolute ground truth can be challenging. That matters because critics sometimes misread these studies as claiming, “Company A is correct; Company B is wrong.”
The 2026 study’s sharper point is comparability and reproducibility. If two services can’t agree on a standardized reference, consumers should be careful treating the readout as a stable personal health marker—especially if they plan to act on it.
The 2026 study’s sharper point is comparability and reproducibility. If two services can’t agree on a standardized reference, consumers should be careful treating the readout as a stable personal health marker—especially if they plan to act on it.
Clostridium, five-fold swings, and non-detection: what disagreement looks like
Disagreement can sound abstract until you see it attached to a specific microbe. Reporting on the 2026 paper offered a vivid example involving Clostridium.
According to MedicalXpress’s write-up, the American Gut Project average for Clostridium was just over 2.5%. Against that backdrop, one company reportedly returned a value around five times higher, and three other services failed to detect it in one or more of the identical samples.
Those are not minor rounding differences. They imply that a consumer could receive:
- A report suggesting Clostridium is a modest, ordinary presence
- A report implying it is unusually high
- A report implying it is absent—or below detection—altogether
Even careful readers can struggle to interpret what “not detected” means. Is the microbe truly absent? Or did the pipeline miss it? Was the threshold too high? Did the reference database differ? The consumer can’t audit the underlying choices, yet the downstream advice may still be delivered with confidence.
According to MedicalXpress’s write-up, the American Gut Project average for Clostridium was just over 2.5%. Against that backdrop, one company reportedly returned a value around five times higher, and three other services failed to detect it in one or more of the identical samples.
Those are not minor rounding differences. They imply that a consumer could receive:
- A report suggesting Clostridium is a modest, ordinary presence
- A report implying it is unusually high
- A report implying it is absent—or below detection—altogether
Even careful readers can struggle to interpret what “not detected” means. Is the microbe truly absent? Or did the pipeline miss it? Was the threshold too high? Did the reference database differ? The consumer can’t audit the underlying choices, yet the downstream advice may still be delivered with confidence.
2.5%
The American Gut Project average for Clostridium was just over 2.5%, yet companies reported values ~5× higher or failed to detect it.
Why “relative abundance” can mislead when methods diverge
Most consumer tests report relative abundance: the percentage of the sample attributed to each microbe. Relative measures are sensitive to the entire measurement process. If one company is better at detecting a certain group, it can shift the whole distribution.
Without robust standardization, two services can produce different “percentages” even if they start with the same biological material. For consumers, it means the apparent precision—a number with a decimal—may conceal a surprisingly fragile foundation.
Without robust standardization, two services can produce different “percentages” even if they start with the same biological material. For consumers, it means the apparent precision—a number with a decimal—may conceal a surprisingly fragile foundation.
A decimal point can look like certainty. In microbiome testing, it can also be a mirage.
— — TheMurrow
The European warning shot: one stool sample, six services, conflicting verdicts
The 2026 NIST-based study is not the first time researchers have shown that “same sample, different answers” is more than an anecdote.
A paper published December 18, 2024 in Microbiome (BMC/Springer Nature) titled “Microbiome testing in Europe: navigating analytical, ethical and regulatory challenges” drew on an interdisciplinary effort: 21 experts from 8 countries, spanning academia, industry, regulators, reference labs, and more.
As reported by Le Monde in May 2025, the organizers submitted a single stool sample to six commercial testing services—five European and one American, including two medical laboratories. The resulting assessments varied widely, including conflicting judgments about microbial diversity—e.g., one provider calling it “excellent” while another deemed it “unfavorable.”
That kind of contradiction hits consumers where it hurts: not at the level of obscure taxa, but at the headline conclusion. “Excellent” and “unfavorable” aren’t scientific synonyms; they are lifestyle verdicts.
A paper published December 18, 2024 in Microbiome (BMC/Springer Nature) titled “Microbiome testing in Europe: navigating analytical, ethical and regulatory challenges” drew on an interdisciplinary effort: 21 experts from 8 countries, spanning academia, industry, regulators, reference labs, and more.
As reported by Le Monde in May 2025, the organizers submitted a single stool sample to six commercial testing services—five European and one American, including two medical laboratories. The resulting assessments varied widely, including conflicting judgments about microbial diversity—e.g., one provider calling it “excellent” while another deemed it “unfavorable.”
That kind of contradiction hits consumers where it hurts: not at the level of obscure taxa, but at the headline conclusion. “Excellent” and “unfavorable” aren’t scientific synonyms; they are lifestyle verdicts.
Different questions, different products
One reason these comparisons end in chaos is that companies aren’t all answering the same question. Some focus on broad taxonomy; others emphasize proprietary scores; some tie outputs to dietary advice. Without shared definitions—what counts as “diverse,” “balanced,” or “healthy”—consumers are left comparing incompatible products.
The European paper framed the problem as not only analytical, but also ethical and regulatory. When a test carries health-adjacent language, the consequences of inconsistency aren’t merely academic. They can influence diets, supplement spending, anxiety levels, and medical decision-making.
The European paper framed the problem as not only analytical, but also ethical and regulatory. When a test carries health-adjacent language, the consequences of inconsistency aren’t merely academic. They can influence diets, supplement spending, anxiety levels, and medical decision-making.
Where the variability likely comes from: the hidden pipeline you never see
When consumers imagine a microbiome test, they imagine sequencing—reading genetic material and listing microbes. The uncomfortable reality is that sequencing is only one step in a longer chain where divergence can accumulate.
Researchers have highlighted multiple sources of analytical variability across the DTC ecosystem:
- Methods and protocols used to process stool material
- Databases used to match sequences to microbial names
- Bioinformatic pipelines and software choices
- Thresholds for detection and reporting
- Scoring systems that translate messy biology into a single “health” number
A Communications Biology report emphasizing “major implications” for comparing tests is effectively pointing at the same thing: you can’t treat two services as interchangeable instruments if they do not measure the same way.
Researchers have highlighted multiple sources of analytical variability across the DTC ecosystem:
- Methods and protocols used to process stool material
- Databases used to match sequences to microbial names
- Bioinformatic pipelines and software choices
- Thresholds for detection and reporting
- Scoring systems that translate messy biology into a single “health” number
A Communications Biology report emphasizing “major implications” for comparing tests is effectively pointing at the same thing: you can’t treat two services as interchangeable instruments if they do not measure the same way.
Reproducibility is a consumer feature, not a lab obsession
Scientists care about reproducibility because it underpins credible knowledge. Consumers should care because reproducibility underpins credible decisions.
If one company’s result can’t be meaningfully compared with another’s, the market becomes a hall of mirrors: people chase a “better” result by switching services, or interpret divergence as alarming biological change. The 2026 finding that between-company variability can resemble between-person variability is a stark warning against that spiral.
If one company’s result can’t be meaningfully compared with another’s, the market becomes a hall of mirrors: people chase a “better” result by switching services, or interpret divergence as alarming biological change. The 2026 finding that between-company variability can resemble between-person variability is a stark warning against that spiral.
Key Insight
If switching companies can look like switching bodies, “shopping for a second opinion” may amplify confusion rather than clarify it.
What these tests can still be good for—if you keep your expectations intact
It would be easy, and lazy, to declare the entire category useless. The research doesn’t support that blanket dismissal. The more accurate conclusion is narrower: many DTC microbiome outputs are not yet reliable enough for individualized health claims, especially when framed as precise diagnostics or prescriptive guidance.
Still, some legitimate uses remain.
Still, some legitimate uses remain.
Curiosity and education—within limits
A microbiome test can be an engaging way to learn about microbial ecology and the general idea that guts differ. For readers who treat it like educational content—akin to a museum exhibit rather than a medical exam—the risk of harm is lower.
The danger comes when curiosity is packaged as clinical authority: a score that implies disease risk, or supplement advice that feels like a prescription.
The danger comes when curiosity is packaged as clinical authority: a score that implies disease risk, or supplement advice that feels like a prescription.
Tracking within one system may be more sensible than shopping between systems
The 2026 study warns most strongly about comparisons across companies. It also suggests caution even for repeat testing, but the headline threat to consumers is the temptation to treat competing services as cross-checks. If you must test, sticking to a single service may reduce one major source of variability—method changes.
That is not an endorsement of accuracy. It is a pragmatic attempt to avoid comparing apples to aircraft.
That is not an endorsement of accuracy. It is a pragmatic attempt to avoid comparing apples to aircraft.
When to bring a clinician into the loop
The research emphasizes avoiding unvalidated conclusions. A clinician can help interpret symptoms and prioritize evidence-based tests. Microbiome sequencing, in most routine settings, is not a substitute for medically indicated diagnostics.
If a report triggers anxiety—“unfavorable” diversity, “imbalanced” ecosystem—consider treating it as a prompt to discuss symptoms and lifestyle broadly, not as a result to “fix” with an expensive supplement stack.
If a report triggers anxiety—“unfavorable” diversity, “imbalanced” ecosystem—consider treating it as a prompt to discuss symptoms and lifestyle broadly, not as a result to “fix” with an expensive supplement stack.
Practical takeaways for readers considering a gut microbiome test
The most responsible consumer posture is neither blind trust nor reflexive cynicism. It is disciplined skepticism—especially when companies translate uncertain measurements into confident recommendations.
Use a hard checklist before you buy
Ask, explicitly, what you are purchasing:
- A taxonomy snapshot (descriptive)
- A proprietary score (interpretive)
- Dietary/supplement guidance (prescriptive)
The further you move from description to prescription, the higher the bar for evidence. The research summarized here shows that even the descriptive layer can vary substantially between services.
- A taxonomy snapshot (descriptive)
- A proprietary score (interpretive)
- Dietary/supplement guidance (prescriptive)
The further you move from description to prescription, the higher the bar for evidence. The research summarized here shows that even the descriptive layer can vary substantially between services.
Before you buy, ask what you’re actually getting
- ✓A taxonomy snapshot (descriptive)
- ✓A proprietary score (interpretive)
- ✓Dietary/supplement guidance (prescriptive)
Treat “health scores” as opinions built on shifting sand
If seven services can disagree on identical material, a single composite “gut health score” should be interpreted as a company-specific construct, not a universal medical marker. A score may be internally consistent within a company’s framework, but it is not necessarily comparable across services—or anchored to clinical outcomes.
Don’t let contradictory results become self-fulfilling anxiety
The Le Monde-reported European experiment showed how one sample can be labeled “excellent” by one service and “unfavorable” by another. That contradiction does not mean your gut suddenly changed personalities. It means the measurement and interpretation differ.
When in doubt, return to first principles: symptoms, clinical history, and evidence-based care.
When in doubt, return to first principles: symptoms, clinical history, and evidence-based care.
Conclusion: The microbiome is real. The consumer readout often isn’t ready.
Microbiome science is not a fraud; it’s a young, complex field. The problem is the mismatch between what the science can robustly support for individuals and what consumer testing companies often sell.
The February 2026 Communications Biology study did consumers a favor by using a NIST-developed standardized stool reference and sending three identical samples to seven services. The resulting disagreement—sometimes as large as the difference between two people—should reset expectations. It suggests that many DTC gut microbiome reports are better viewed as company-specific interpretations than as stable personal health facts.
The earlier European effort—one stool sample submitted to six services, producing “excellent” versus “unfavorable” verdicts—adds a cultural footnote with the same moral: your microbiome may be variable, but the marketplace is, too.
The next phase of this field should look less like personalized lifestyle theater and more like measurement discipline: transparency, standards, reproducibility, and clear boundaries between research curiosity and medical advice. Until then, treat microbiome reports with the same caution you’d give any alluring number that can’t explain how it earned your trust.
The February 2026 Communications Biology study did consumers a favor by using a NIST-developed standardized stool reference and sending three identical samples to seven services. The resulting disagreement—sometimes as large as the difference between two people—should reset expectations. It suggests that many DTC gut microbiome reports are better viewed as company-specific interpretations than as stable personal health facts.
The earlier European effort—one stool sample submitted to six services, producing “excellent” versus “unfavorable” verdicts—adds a cultural footnote with the same moral: your microbiome may be variable, but the marketplace is, too.
The next phase of this field should look less like personalized lifestyle theater and more like measurement discipline: transparency, standards, reproducibility, and clear boundaries between research curiosity and medical advice. Until then, treat microbiome reports with the same caution you’d give any alluring number that can’t explain how it earned your trust.
T
About the Author
TheMurrow Editorial is a writer for TheMurrow covering health & wellness.
Frequently Asked Questions
Why do different gut microbiome companies give different results?
Independent research shows that analytical variability plays a major role. Different services can use different lab methods, reference databases, and computational pipelines, plus different thresholds for reporting microbes. A February 2026 Communications Biology study found seven services produced meaningfully different results even when given three identical standardized samples, pointing to the testing process—not just biology—as a key driver.
Does the 2026 NIST study prove one company is “right” and the others are wrong?
No. A nuance highlighted in ACS/C&EN coverage is that establishing a perfect “ground truth” for even a standardized stool sample can be difficult. The study’s main value is demonstrating comparability and reproducibility problems: if services can’t agree on standardized material, consumers should be cautious about treating the results as stable or clinically meaningful.
Are microbiome “gut health scores” medically validated?
The research summarized here raises serious concerns about treating such scores as reliable health markers, especially across companies. If services disagree on basic microbial detection and abundance in identical samples, then composite scores built on those measurements can be even more fragile. Without validated clinical evidence tied to outcomes, treat scores as company-specific interpretations, not diagnoses.
If I repeat the test, will I get the same result?
Not necessarily. The microbiome can change naturally, but the bigger concern from recent research is that methods can produce different outputs even when biology is controlled. The 2026 study specifically warns about comparing results between companies, and it also urges caution about overinterpreting changes, especially if decisions hinge on small shifts.
Should I take probiotics or supplements based on a DTC microbiome test?
Be careful. Many services pair results with supplement or probiotic recommendations, but the research indicates that the underlying measurements can vary substantially between providers. If a recommendation is based on microbes that another service might not even detect, that’s a warning sign. Consider discussing symptoms and evidence-based options with a clinician rather than treating the report as a prescription.
What’s the most responsible way to use a gut microbiome test?
Use it primarily for education and curiosity, not as a diagnostic tool. Avoid comparing results across different companies as if they were cross-checking the same measurement. If a report triggers concern—like an “unfavorable” rating—treat it as a prompt to reflect on diet and health habits broadly and to seek medical advice for symptoms, rather than as a definitive statement about disease or risk.
